Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Completed · Phase 2 · Has a placebo group
Conditions studied: PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten, Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
In brief
This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow disease progression in patients with localized prostate cancer.
Key facts
- Study ID
- NCT02095145
- Run by
- National Cancer Institute (NCI)
- People needed
- 38
- Starts
- 2014-05-08
- Expected to finish
- 2019-09-26
- Last updated by the study team
- 2020-02-05
Who can join
Age: 21 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have had a standard-of-care biopsy within 13 months of the baseline study visit and must have been diagnosed with low-grade, clinically localized prostate cancer (Gleason score =< 3+3 with a PSA at baseline < 10 ng/ml in participants < 70 years of age, OR Gleason score =< 3+4 with a PSA at baseline =< 15 ng/ml in participants >= 70 years of age); eligible participants will be those men who are able and willing to undergo AS with PSA monitoring and a scheduled biopsy performed at the end of the study
- No concurrent treatment (hormonal, radiation or systemic chemotherapy) for prostate cancer during study enrollment is planned (unless participants demonstrate clinical evidence of prostate cancer progression such as symptoms, physical exam findings, a rapidly increasing PSA, or radiologic findings which confirm disease progression)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1
- White blood cells (WBC) >= 3000/mm\^3
- Platelets >= 100,000 mm\^3
- Hemoglobin >= 10 g/dL
- Total bilirubin =< 1.5 x upper limit of institutional normal
- Alkaline phosphatase =< 1.5 x upper limit of institutional normal
- Aspartate aminotransferase (AST) =< 1.5 x upper limit of institutional normal
- Alanine aminotransferase (ALT) =< 1.5 x upper limit of institutional normal
- Serum creatinine within 1.5 x upper limit of institutional normal
- Sodium 135-144 mmol/L (inclusive)
- Potassium 3.2-4.8 mmol/L (inclusive)
- Participants will be required to use a medically-approved method of birth control or abstinence if their sexual partner is of child-bearing potential
- Participants must be willing to forego foods, beverages and supplements containing pomegranate for the duration of the study
- Ability to understand, and the willingness to sign, a written informed consent document
You may not qualify if…
- Any prior surgery to the prostate within 30 days of baseline procedures; NOTE: Biopsies are not considered surgeries
- Evidence of other cancer(s) (excluding non-melanoma skin cancer) within last 5 years
- Prior pelvic radiation for any reason
- Participants cannot be taking 5-alpha-reductase inhibitors while on study or within 6 months of the baseline study visit
- Participants may not be taking carbamazepine (tegretol)
- Participants may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PFE
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
- Any significant cardiac event(s) within the 12 months prior to registration, such as episode(s) of symptomatic congestive heart failure, myocardial infarction, unstable angina pectoris or persistent, stable angina pectoris, or cardiac arrhythmia requiring medication
Where it is running
- Lahey Hospital and Medical Center — Burlington, Massachusetts, United States
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota, United States
- Urology San Antonio Research PA — San Antonio, Texas, United States
- University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.